259 related articles for article (PubMed ID: 12556350)
1. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350
[TBL] [Abstract][Full Text] [Related]
2. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R
Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088
[TBL] [Abstract][Full Text] [Related]
3. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
Hegarty BD; Furler SM; Oakes ND; Kraegen EW; Cooney GJ
Endocrinology; 2004 Jul; 145(7):3158-64. PubMed ID: 15059948
[TBL] [Abstract][Full Text] [Related]
5. Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.
Wierzbicki M; Chabowski A; Zendzian-Piotrowska M; Harasim E; Górski J
Adv Med Sci; 2009; 54(1):59-65. PubMed ID: 19403437
[TBL] [Abstract][Full Text] [Related]
6. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
7. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Tsunoda M; Kobayashi N; Ide T; Utsumi M; Nagasawa M; Murakami K
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E833-40. PubMed ID: 18212024
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation.
Ye JM; Doyle PJ; Iglesias MA; Watson DG; Cooney GJ; Kraegen EW
Diabetes; 2001 Feb; 50(2):411-7. PubMed ID: 11272155
[TBL] [Abstract][Full Text] [Related]
9. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
Kannisto K; Chibalin A; Glinghammar B; Zierath JR; Hamsten A; Ehrenborg E
Int J Mol Med; 2006 Jan; 17(1):45-52. PubMed ID: 16328010
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
12. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
13. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
15. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
[TBL] [Abstract][Full Text] [Related]
16. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
17. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
[TBL] [Abstract][Full Text] [Related]
18. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
Ide T; Tsunoda M; Mochizuki T; Murakami K
Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance.
Todd MK; Watt MJ; Le J; Hevener AL; Turcotte LP
Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E485-93. PubMed ID: 17003244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]